Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZYN-004
- Development stage
- Preclinical
- Lead developer
- zyvran pharmaceuticals
- Modality
- Small Molecules
01
Overview
ZYN-004 (A2121X) is an investigational combination drug candidate being developed by Zyvran Pharmaceuticals for the treatment of mixed pain states. The candidate is specifically targeted toward neuropathic pain conditions, including post-spinal surgery syndrome, chemotherapy-induced neuropathy, and diabetic peripheral neuropathy. As part of Zyvran's focus on multi-pathway combination therapies, ZYN-004 is designed to target multiple pain pathways simultaneously to improve therapeutic efficacy and reduce side effects compared to single-agent treatments, though its exact active ingredients and molecular targets remain undisclosed.
Beyond the preview
Go deeper on ZYN-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZYN-004.